Trastuzumab deruxtecan for advanced breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a targeted therapy called trastuzumab deruxtecan for people with advanced breast cancer. It aims to see how well the treatment works and how safe it is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You must have advanced breast cancer and your doctor recommends trastuzumab deruxtecan as a treatment option.
- You must be in good enough physical condition to be up and about (ECOG score 0 or 1).
- You cannot be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two new antibody-based drugs (trastuzumab rezetecan and trastuzumab deruxtecan) designed to treat advanced breast cancer that has spread or cannot be removed with surgery. These drugs target HER2, a protein found on certain cancer cells, and may help patients whose cancer has progressed after previous treatment with trastuzumab and chemotherapy.
This Phase 2 trial studies trastuzumab deruxtecan (T‑DXd) as a first treatment for people with HER2‑low, triple‑negative breast cancer that has spread or returned and cannot be fully removed by surgery. It aims to shrink tumors and control the disease while checking safety and side effects.
This trial tests a combination of two targeted drugs — anlotinib (which cuts off a tumor's blood supply) and trastuzumab deruxtecan (which attacks HER2-low cancer cells) — for advanced breast cancer that has stopped responding to previous treatments.
This study looks at how well the drug trastuzumab deruxtecan works in women with breast cancer that has spread. It is for patients who have already taken this drug.
This trial tests whether a targeted drug called trastuzumab deruxtecan can help people with advanced HER2-positive stomach, esophageal, or gastroesophageal junction cancer. It's for those who haven't had chemotherapy for metastatic disease and are not able to get combination therapy.
This trial tests a new drug, trastuzumab rezetecan, for women with breast cancer that has come back or spread and cannot be removed by surgery. It's for those who haven't had chemotherapy for advanced disease but have tried hormone therapy and it stopped working.
Hear when a new Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.